Press Releases

Onboarding of Traceability Customers Continues to Accelerate; Company Ends Quarter with $24.5 Million in Cash, No Debt

SALT LAKE CITY--(BUSINESS WIRE)-- ReposiTrak (NYSE: TRAK), the world's largest food traceability and regulatory compliance network, built upon its proven inventory management and out-of-stock reduction SaaS platform, today announced financial results for the third fiscal quarter (“FQ3 2024”) ended March 31, 2024.

Third Quarter Financial... (continue reading...)

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Chegg, Inc. (NYSE: CHGG) today announced the newest members of its Academic Advisory Board, strengthening its presence in the UK and Australia, and further reinforcing its commitment to student learning success and academic integrity. To ensure the student voice is strongly represented alongside that of leading academics, Chegg also launched a new Student Advisory Council.

This press release features multimedia. View the full... (continue reading...)

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.

WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and... (continue reading...)

• On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024
• Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI
• Received FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPA
• Cash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025

CAMBRIDGE, Mass.,... (continue reading...)

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

Recent Highlights

• Announced global commercialization partnership with Bio-Rad Laboratories, Inc.
• On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development... (continue reading...)